Open-label Extension to Protocol 1042-0600

This is an open-label study evaluating efficacy and safety of ganaxolone treatment in adults with partial onset epilepsy with or without secondary generalizations.

Inclusion criteria

• Participants who have completed all scheduled clinical study visits in the previous protocol 1042-0600 and have been deemed eligible (no major adverse events thought to be drug related) by the Investigator.
• Diagnosis of epilepsy with CPS with or without secondarily generalized seizures according to the International League Against Epilepsy [ILAE] Classification of Epileptic Seizures (1981). Diagnosis should have been established by clinical history and computerized tomography (CT) or magnetic resonance imaging (MRI) of the brain to rule out progressive structural lesions and electroencephalogram (EEG) or video EEG with results consistent with partial-onset epilepsy.
• Male or female, 18 to 69 years of age (inclusive). [Note: Participants who are > 69 years of age but are of good health condition may be allowed to enter the study after discussion with and approval by the Medical Monitor.]
• A 12-lead electrocardiogram (ECG) without clinically significant abnormalities.
• Be properly informed of the nature and risks of the study and give informed consent in writing, prior to entering the study.
• Able to participate for the full term of study.
• Able to keep a seizure diary throughout the course of the study.
• Sexually active women of childbearing potential must be using a medically acceptable method of birth control and have a negative qualitative serum beta-human chorionic growth hormone (beta HCG) pregnancy test result from a blood sample collected at the initial screening visit. A woman of childbearing potential is defined as a female who is biologically capable of becoming pregnant. A medically acceptable method of birth control includes intrauterine devices in place for at least 3 months, surgical sterilization, or adequate barrier methods (e.g., diaphragm and foam). An oral contraceptive alone is not considered adequate for the purpose of this study. Use of oral contraceptives in combination with another method (e.g., a spermicidal cream) is acceptable. In participants who are not sexually active, abstinence is an acceptable form of birth control and qualitative serum βHCG pregnancy tests must be tested per protocol.
• Participants with a history of depression must be stable and may be taking one antidepressant medication

Exclusion criteria

• Presence of non-motor simple partial seizures only.
• History of pseudoseizures in the last 5 years.
• History of a primary generalized seizure in the last 5 years.
• Past use of vigabatrin without stable visual fields tested twice over the 12 months after the last dose of vigabatrin (Concomitant use of vigabatrin is not allowed).
• Seizures secondary to illicit drug or alcohol use, infection, neoplasm, demyelinating disease, degenerative neurological disease, or CNS disease deemed progressive, metabolic illness, or progressive degenerative disease.
• Status epilepticus within the last year prior to randomization in 1042-0600 study.
• Clinically unstable psychiatric disorder within the last 2 years.
• Suicide attempt within the last 5 years or current significant suicidal ideation.
• History of psychosis within the last 5 years.
• Current use of neuroleptics for psychosis.
• A significant medical or surgical condition at screening which might compromise the hematologic, cardiovascular, pulmonary, renal, gastrointestinal, or hepatic systems or other conditions that would place the participant at increased risk.
• Known sensitivity or allergy to progesterone or related steroid compounds.
• History of drug use or alcohol abuse within the past 5 years.
• Sexually active women of childbearing potential (WCBP) who are unwilling to use a double-barrier method and establish that they are currently not pregnant by submitting to a serum pregnancy test.
• A history of chronic noncompliance with drug regimens.
• Females who are currently breastfeeding.
• Exposure to any other investigational drug within 30 days prior to randomization in 1042-0600 study.
• Aspartate transaminase (AST) or alanine transaminase (ALT) levels > 3 times the upper limit of normal (ULN) at screening.
• Participant has history of repetitive seizures within the 12-month period preceding study entry where the individual seizures cannot be counted.
• Inability to withhold grapefruit and grapefruit juice from diet during the entire clinical trial.